JP Morgan Chase
SCNI

JP Morgan Chase’s Scinai Immunotherapeutics SCNI Stock Holding History

JP Morgan Chase’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3
Closed -$1K – 6955
2021
Q4 		$1K Buy
+3
New +$619 ﹤0.01% 6569
2021
Q1 		– Sell
-2
Closed – – 6315
2020
Q4 		$0 Buy
+2
New +$2.42K ﹤0.01% 5893
2020
Q2 		– Sell
-2
Closed -$1K – 5662
2020
Q1 		$1K Buy
+2
New +$1.77K ﹤0.01% 5214

Other funds holding SCNI

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TPWA
TRUE Private Wealth Advisors Salem, Oregon $1.16B AUM 36.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase's SCNI Position: Q1 2022 in Review

JP Morgan Chase sold out of Scinai Immunotherapeutics (SCNI) in Q1 2022, closing a stake of 3 shares — an estimated $1K sold.

JP Morgan Chase first reported a position in SCNI in Q1 2020 and held it in 3 quarters. The position peaked at $1K in Q4 2021. 18 funds tracked by Wall St. Rank hold SCNI as of Q1 2022.

  • JP Morgan Chase reported no remaining Scinai Immunotherapeutics position as of Q1 2022 after selling out during the quarter.
  • JP Morgan Chase sold 3 Scinai Immunotherapeutics shares in Q1 2022, an estimated $1K.
  • JP Morgan Chase first reported a position in Scinai Immunotherapeutics in Q1 2020 and held it in 3 quarters.
  • JP Morgan Chase's Scinai Immunotherapeutics position peaked at $1K in Q4 2021.
  • 18 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q1 2022.

Based on JP Morgan Chase's 13F filing for Q1 2022, filed 11 May 2022.